Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO

Xiaowei ZHANG; Xin LIU; Zhiguo LUO

doi:10.19401/j.cnki.1007-3639.2023.11.003

您当前的位置：

首页 >

文章列表页 >

Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO

Specialist' Commentary | 更新时间：2025-12-31

- Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO
- China Oncology Vol. 33, Issue 11, Pages: 989-992(2023)
- 作者机构：
  
  复旦大学附属肿瘤医院大内科，复旦大学上海医学院肿瘤学系，上海 200032；
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.11.003
  CLC： R730.5
- Received：15 November 2023，
  
  Revised：2023-11-18，
  
  Published：30 November 2023
- 稿件说明：
移动端阅览
Xiaowei ZHANG, Xin LIU, Zhiguo LUO. Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO[J]. China Oncology, 2023, 33(11): 989-992.
DOI：

Xiaowei ZHANG, Xin LIU, Zhiguo LUO. Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO[J]. China Oncology, 2023, 33(11): 989-992. DOI： 10.19401/j.cnki.1007-3639.2023.11.003.

摘要

原发灶不明肿瘤（cancer of unknown primary，CUP）是一类组织学上确定为转移并经过一系列检查仍未找到原发灶的肿瘤，占所有新发肿瘤的2%~5%。CUP具有侵袭性强、早期转移及预后差等特征。随着新兴基因检测和药物的应用，基因表达谱和基因组检测在揭示肿瘤分子特征中的价值日益凸显，基于分子指导的靶向治疗和免疫治疗等新的治疗选择也应运而生。本文就2023年欧洲肿瘤学会（European Society for Medical Oncology，ESMO）年会上报道的有关CUP的临床试验进行述评。

Abstract

Cancer of unknown primary (CUP) is a metastatic syndrome with an unidentifiable primary tumor even after comprehensive clinical and pathological investigations

accounting for approximately 2%-5% of all newly diagnosed cancers. CUP has some common features including aggressiveness

early dissemination and poor prognosis. With the application of novel molecular tests and drugs

the diagnostic value of gene expression assay and genomic tests in characterizing the molecular features has become increasingly prominent

and new treatment options such as molecular-guided targeted therapy and immunotherapy have become available. This article reviewed the clinical trials of CUP reported at 2023 European Society for Medical Oncology (ESMO) Congress.

关键词

Keywords

references

KRÄMER A , BOCHTLER T , PAULI C , et al . Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2023 , 34 ( 3 ): 228 - 246 . DOI: 10.1016/j.annonc.2022.11.013 http://doi.org/10.1016/j.annonc.2022.11.013 https://linkinghub.elsevier.com/retrieve/pii/S092375342204769X https://linkinghub.elsevier.com/retrieve/pii/S092375342204769X

RASSY E , PAVLIDIS N . The currently declining incidence of cancer of unknown primary [J ] . Cancer Epidemiol , 2019 , 61 : 139 - 141 . DOI: S1877-7821(19)30056-6 http://doi.org/S1877-7821(19)30056-6

SUN W , WU W , WANG Q F , et al . Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients [J ] . J Transl Med , 2022 , 20 ( 1 ): 114 . DOI: 10.1186/s12967-022-03318-6 http://doi.org/10.1186/s12967-022-03318-6

LUO Z , LIU X , ZHANG X , et al . A randomized phase Ⅲ trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary [J ] . Ann Oncol , 2023 , 34 : S712 .

HAINSWORTH J D , RUBIN M S , SPIGEL D R , et al . Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute [J ] . J Clin Oncol , 2013 , 31 ( 2 ): 217 - 223 . DOI: 10.1200/JCO.2012.43.3755 http://doi.org/10.1200/JCO.2012.43.3755

MORAN S , MARTÍNEZ-CARDÚS A , SAYOLS S , et al . Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis [J ] . Lancet Oncol , 2016 , 17 ( 10 ): 1386 - 1395 . DOI: S1470-2045(16)30297-2 http://doi.org/S1470-2045(16)30297-2

HAYASHI H , TAKIGUCHI Y , MINAMI H , et al . Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 12 ): 1931 - 1938 . DOI: 10.1001/jamaoncol.2020.4643 http://doi.org/10.1001/jamaoncol.2020.4643

HAYASHI H , KURATA T , TAKIGUCHI Y , et al . Randomized phase Ⅱ trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site [J ] . J Clin Oncol , 2019 , 37 ( 7 ): 570 - 579 .

FIZAZI K , MAILLARD A , PENEL N , et al . A phase Ⅲ trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04) [J ] . Ann Oncol , 2019 , 30 : v851 .

MILESHKIN L . Primary analysis of efficacy and safety in the CUPISCO trial: a randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP) [J ] . Ann Oncol , 2023 , 34 : S1254 -S1255. DOI: 10.1016/j.annonc.2023.10.006 http://doi.org/10.1016/j.annonc.2023.10.006 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041509 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041509

Views

2047

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cancer of unknown primary: recent advancements in the diagnosis and treatment

Current status and future prospects of clinical trials for radioiodine-refractory thyroid cancer

China Anti-Cancer Association guideline for diagnosis and treatment of cancer of multiple and unknown primaries (2023 edition)

The progress of treatment for triple-negative breast cancer in the era of precision medicine

Related Author

Ting ZHAO

Xiaowei ZHANG

Xin LIU

Qifeng WANG

Xichun HU

Zhiguo LUO

Ruping LI

Hui YANG

Related Institution

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Pathology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

Key Laboratory of Precision Diagnosis and Treatment in Oncology Nuclear Medicine for Henan Provincial

山东省肿瘤防治研究院（山东省肿瘤医院），山东第一医科大学（山东省医学科学院），乳腺病中心

AI问答

⁰